A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasisYu Chen, Gang Wang, Furen Zhang et al.|International Immunopharmacology|2022Cited by 12
Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trialKun Huang, Min Zheng, Chao Ji et al.|Chinese Medical Journal|2025Cited by 0